Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
NCT06450106 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18
Last updated 2026-02-19
Summary
A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy
Conditions
Interventions
- DRUG
-
STM-416p
STM-416p monotherapy
Sponsors & Collaborators
-
SURGE Therapeutics
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-05-08
- Primary Completion
- 2026-09-30
- Completion
- 2026-12-31
- FDA Drug
- Yes
Countries
- United States
- Australia
Study Locations
More Related Trials
-
A Study Into the Effectivity and Safety of Firmagon, Prescribed for Treatment of Patients With Advanced Prostate Cancer
NCT01215526 ·Status: COMPLETED
-
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
NCT05534646 ·Status: RECRUITING ·Phase: PHASE2
-
EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T
NCT05521412 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer
NCT00502164 ·Status: COMPLETED ·Phase: PHASE1
-
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
NCT05352178 ·Status: RECRUITING ·Phase: PHASE3
-
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025 ·Status: RECRUITING ·Phase: PHASE3
-
Selective Treatment According to Molecular Subtype of Prostate Cancer
NCT03696186 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer
NCT00058539 ·Status: COMPLETED ·Phase: PHASE2
-
Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer
NCT00134355 ·Status: COMPLETED ·Phase: PHASE2
-
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
NCT00028769 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
NCT05800665 ·Status: RECRUITING ·Phase: PHASE1
-
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery
NCT01923506 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Impact of Adjuvant Statin Therapy in Patients Who Underwent Radical Prostatectomy for Locally Advanced Prostate Cancer
NCT01759836 ·Status: COMPLETED ·Phase: PHASE2
-
AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer
NCT00519233 ·Status: COMPLETED ·Phase: PHASE1
-
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
NCT00170157 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy
NCT00790595 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer
NCT01734681 ·Status: WITHDRAWN ·Phase: PHASE2
-
An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients
NCT00235794 ·Status: COMPLETED ·Phase: NA
-
A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer
NCT01337518 ·Status: SUSPENDED ·Phase: PHASE1
-
An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer
NCT04089553 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
NCT01228760 ·Status: COMPLETED ·Phase: PHASE1
-
An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Prostatic Adenocarcinoma
NCT03061643 ·Status: UNKNOWN ·Phase: PHASE2
-
Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
NCT00669162 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT02705469 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT02711956 ·Status: COMPLETED ·Phase: PHASE1/PHASE2